Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific
AIMS Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interpho...
Gespeichert in:
Veröffentlicht in: | British journal of ophthalmology 1997-01, Vol.81 (1), p.61-67 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 67 |
---|---|
container_issue | 1 |
container_start_page | 61 |
container_title | British journal of ophthalmology |
container_volume | 81 |
creator | Laliotou, Barbara Liversidge, Janet Forrester, John V Dick, Andrew D |
description | AIMS Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interphotoreceptor retinoid binding protein (IRBP) are two major autoantigens within soluble RE. It was aimed to assess, firstly, as has previously been shown with S-Ag, if IRBP can induce intranasal tolerance and, secondly, the contribution of both these major autoantigens to tolerance induction by whole RE. METHODS Animals were tolerised by intranasal administration with S-Ag or IRBP, either alone or in combination, or RE before immunisation with either IRBP or RE. Control animals were administered nasally either PBS or MBP. Daily clinical responses were recorded biomicroscopically and histological grades were obtained using a semiquantitative scoring system. Weekly serum antibody levels to retinal antigens were measured by ELISA and delayed hypersensitivity responses (DTH) were assessed by skin reactivity to intradermal inoculation with retinal or non-specific antigens. RESULTS Microgram doses of IRBP successfully suppressed both clinically and histologically IRBP induced EAU. This suppression was accompanied by reduced antigen specific DTH reactivity but maintained T cell dependent (IgG2a) antibody responses. Furthermore, combined S-Ag and IRBP administration afforded equal suppression of RE induced EAU when compared with RE therapy alone. Suppression of RE induced EAU was not achieved with administration of a non-retinal specific autoantigen, MBP. Although individually, both S-Ag and IRBP suppressed RE induced EAU, whole RE was unable to protect against IRBP induced disease. CONCLUSIONS Intranasal administration of IRBP suppressed IRBP induced EAU in the Lewis rat. S-Ag and IRBP are the major contributors to the tolerogenicity within RE, despite the known uveogenicity of other retinal antigens within RE and induction of tolerance was retinal antigen specific. Furthermore, suppression induced by single antigen administration is antigen specific although concomitant bystander suppression may also play a role. RE was unable to protect against IRBP induced disease despite tolerogenic levels of antigen within RE. Although this may be due in part to a dose effect of either tolerising or immunising antigen, further investigation into the possible antigen dominance of IRBP |
doi_str_mv | 10.1136/bjo.81.1.61 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1722010</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4012596501</sourcerecordid><originalsourceid>FETCH-LOGICAL-b502t-bf71a787b826528ff15ac994790c8721cb12a422c7f943df1ecbe101b33b5a523</originalsourceid><addsrcrecordid>eNp9kUuP0zAUhSMEGsrAijWSJRAblOLrPJywQEIVAzNUICGYrWW7Nx2XxA62Mwz_hp-KQ6vyWLC6ts93j499s-wh0CVAUT9XO7dsYAnLGm5lCyjrJmeUt7ezBaWU5wA13M3uhbBLW1YDP8lOWiiqEmCR_Ti3Ef145aLzqHFMhXiMxjqzIcrYjbFbMnoX0VhiApFkTGsbSXQ9erfFdGrJGr8lzcv4goRpHD2GYJwlriN4M6I3Q-qQPZFTdGYYJotkukb36x4TU-fcPG9mxkYzu4YRtemMvp_d6WQf8MGhnmafz15_Wr3N1x_enK9erXNVURZz1XGQvOGqYXXFmq6DSuq2LXlLdcMZaAVMloxp3rVlsekAtUKgoIpCVbJixWn2cu87TmrAjU6JvezFmMJL_104acTfijVXYuuuBXDGKNBk8PRg4N3XCUMUgwka-15adFMQvGnr9OllAh__A-7c5NPbQ_KaKVZySNSzPaW9C8Fjd4wCVMxjF2nsogEBop7pR3-mP7KHOSf9yUGXQcu-89JqE44Yq5r5kxKW7zETIt4cZem_iJoXvBLvL1fi3eXHi4KzC3H2-81q2P0330-lL9Yu</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778962471</pqid></control><display><type>article</type><title>Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Laliotou, Barbara ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</creator><creatorcontrib>Laliotou, Barbara ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</creatorcontrib><description>AIMS Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interphotoreceptor retinoid binding protein (IRBP) are two major autoantigens within soluble RE. It was aimed to assess, firstly, as has previously been shown with S-Ag, if IRBP can induce intranasal tolerance and, secondly, the contribution of both these major autoantigens to tolerance induction by whole RE. METHODS Animals were tolerised by intranasal administration with S-Ag or IRBP, either alone or in combination, or RE before immunisation with either IRBP or RE. Control animals were administered nasally either PBS or MBP. Daily clinical responses were recorded biomicroscopically and histological grades were obtained using a semiquantitative scoring system. Weekly serum antibody levels to retinal antigens were measured by ELISA and delayed hypersensitivity responses (DTH) were assessed by skin reactivity to intradermal inoculation with retinal or non-specific antigens. RESULTS Microgram doses of IRBP successfully suppressed both clinically and histologically IRBP induced EAU. This suppression was accompanied by reduced antigen specific DTH reactivity but maintained T cell dependent (IgG2a) antibody responses. Furthermore, combined S-Ag and IRBP administration afforded equal suppression of RE induced EAU when compared with RE therapy alone. Suppression of RE induced EAU was not achieved with administration of a non-retinal specific autoantigen, MBP. Although individually, both S-Ag and IRBP suppressed RE induced EAU, whole RE was unable to protect against IRBP induced disease. CONCLUSIONS Intranasal administration of IRBP suppressed IRBP induced EAU in the Lewis rat. S-Ag and IRBP are the major contributors to the tolerogenicity within RE, despite the known uveogenicity of other retinal antigens within RE and induction of tolerance was retinal antigen specific. Furthermore, suppression induced by single antigen administration is antigen specific although concomitant bystander suppression may also play a role. RE was unable to protect against IRBP induced disease despite tolerogenic levels of antigen within RE. Although this may be due in part to a dose effect of either tolerising or immunising antigen, further investigation into the possible antigen dominance of IRBP or mucosal processing of combinations of antigens is necessary so that the full efficacy of mucosal tolerance therapy can be assessed.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjo.81.1.61</identifier><identifier>PMID: 9135411</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Administration, Intranasal ; Animals ; Antigens ; Arrestin - administration & dosage ; Arrestin - immunology ; Autoantigens - administration & dosage ; Autoantigens - immunology ; Autoimmune diseases ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Biological and medical sciences ; Disease ; Drug dosages ; Enzyme-Linked Immunosorbent Assay ; experimental autoimmune uveoretinitis ; Female ; Immune Tolerance - drug effects ; interphotoreceptor retinoid binding protein ; Laboratory Science ; Lymphocytes ; Medical sciences ; Ophthalmology ; Proteins ; Rats ; Rats, Inbred Lew ; Retina - chemistry ; retinal autoantigens ; Retinol-Binding Proteins - administration & dosage ; Retinol-Binding Proteins - immunology ; S-antingen ; Skin Tests ; tolerance ; Uvea diseases ; Uveitis, Posterior - drug therapy ; Uveitis, Posterior - immunology</subject><ispartof>British journal of ophthalmology, 1997-01, Vol.81 (1), p.61-67</ispartof><rights>British Journal of Ophthalmology</rights><rights>1997 INIST-CNRS</rights><rights>Copyright: 1997 British Journal of Ophthalmology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b502t-bf71a787b826528ff15ac994790c8721cb12a422c7f943df1ecbe101b33b5a523</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1722010/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1722010/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,4012,27910,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2588721$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9135411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laliotou, Barbara</creatorcontrib><creatorcontrib>Liversidge, Janet</creatorcontrib><creatorcontrib>Forrester, John V</creatorcontrib><creatorcontrib>Dick, Andrew D</creatorcontrib><title>Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>AIMS Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interphotoreceptor retinoid binding protein (IRBP) are two major autoantigens within soluble RE. It was aimed to assess, firstly, as has previously been shown with S-Ag, if IRBP can induce intranasal tolerance and, secondly, the contribution of both these major autoantigens to tolerance induction by whole RE. METHODS Animals were tolerised by intranasal administration with S-Ag or IRBP, either alone or in combination, or RE before immunisation with either IRBP or RE. Control animals were administered nasally either PBS or MBP. Daily clinical responses were recorded biomicroscopically and histological grades were obtained using a semiquantitative scoring system. Weekly serum antibody levels to retinal antigens were measured by ELISA and delayed hypersensitivity responses (DTH) were assessed by skin reactivity to intradermal inoculation with retinal or non-specific antigens. RESULTS Microgram doses of IRBP successfully suppressed both clinically and histologically IRBP induced EAU. This suppression was accompanied by reduced antigen specific DTH reactivity but maintained T cell dependent (IgG2a) antibody responses. Furthermore, combined S-Ag and IRBP administration afforded equal suppression of RE induced EAU when compared with RE therapy alone. Suppression of RE induced EAU was not achieved with administration of a non-retinal specific autoantigen, MBP. Although individually, both S-Ag and IRBP suppressed RE induced EAU, whole RE was unable to protect against IRBP induced disease. CONCLUSIONS Intranasal administration of IRBP suppressed IRBP induced EAU in the Lewis rat. S-Ag and IRBP are the major contributors to the tolerogenicity within RE, despite the known uveogenicity of other retinal antigens within RE and induction of tolerance was retinal antigen specific. Furthermore, suppression induced by single antigen administration is antigen specific although concomitant bystander suppression may also play a role. RE was unable to protect against IRBP induced disease despite tolerogenic levels of antigen within RE. Although this may be due in part to a dose effect of either tolerising or immunising antigen, further investigation into the possible antigen dominance of IRBP or mucosal processing of combinations of antigens is necessary so that the full efficacy of mucosal tolerance therapy can be assessed.</description><subject>Administration, Intranasal</subject><subject>Animals</subject><subject>Antigens</subject><subject>Arrestin - administration & dosage</subject><subject>Arrestin - immunology</subject><subject>Autoantigens - administration & dosage</subject><subject>Autoantigens - immunology</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Biological and medical sciences</subject><subject>Disease</subject><subject>Drug dosages</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>experimental autoimmune uveoretinitis</subject><subject>Female</subject><subject>Immune Tolerance - drug effects</subject><subject>interphotoreceptor retinoid binding protein</subject><subject>Laboratory Science</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Ophthalmology</subject><subject>Proteins</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Retina - chemistry</subject><subject>retinal autoantigens</subject><subject>Retinol-Binding Proteins - administration & dosage</subject><subject>Retinol-Binding Proteins - immunology</subject><subject>S-antingen</subject><subject>Skin Tests</subject><subject>tolerance</subject><subject>Uvea diseases</subject><subject>Uveitis, Posterior - drug therapy</subject><subject>Uveitis, Posterior - immunology</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUuP0zAUhSMEGsrAijWSJRAblOLrPJywQEIVAzNUICGYrWW7Nx2XxA62Mwz_hp-KQ6vyWLC6ts93j499s-wh0CVAUT9XO7dsYAnLGm5lCyjrJmeUt7ezBaWU5wA13M3uhbBLW1YDP8lOWiiqEmCR_Ti3Ef145aLzqHFMhXiMxjqzIcrYjbFbMnoX0VhiApFkTGsbSXQ9erfFdGrJGr8lzcv4goRpHD2GYJwlriN4M6I3Q-qQPZFTdGYYJotkukb36x4TU-fcPG9mxkYzu4YRtemMvp_d6WQf8MGhnmafz15_Wr3N1x_enK9erXNVURZz1XGQvOGqYXXFmq6DSuq2LXlLdcMZaAVMloxp3rVlsekAtUKgoIpCVbJixWn2cu87TmrAjU6JvezFmMJL_104acTfijVXYuuuBXDGKNBk8PRg4N3XCUMUgwka-15adFMQvGnr9OllAh__A-7c5NPbQ_KaKVZySNSzPaW9C8Fjd4wCVMxjF2nsogEBop7pR3-mP7KHOSf9yUGXQcu-89JqE44Yq5r5kxKW7zETIt4cZem_iJoXvBLvL1fi3eXHi4KzC3H2-81q2P0330-lL9Yu</recordid><startdate>199701</startdate><enddate>199701</enddate><creator>Laliotou, Barbara</creator><creator>Liversidge, Janet</creator><creator>Forrester, John V</creator><creator>Dick, Andrew D</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199701</creationdate><title>Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific</title><author>Laliotou, Barbara ; Liversidge, Janet ; Forrester, John V ; Dick, Andrew D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b502t-bf71a787b826528ff15ac994790c8721cb12a422c7f943df1ecbe101b33b5a523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Administration, Intranasal</topic><topic>Animals</topic><topic>Antigens</topic><topic>Arrestin - administration & dosage</topic><topic>Arrestin - immunology</topic><topic>Autoantigens - administration & dosage</topic><topic>Autoantigens - immunology</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Biological and medical sciences</topic><topic>Disease</topic><topic>Drug dosages</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>experimental autoimmune uveoretinitis</topic><topic>Female</topic><topic>Immune Tolerance - drug effects</topic><topic>interphotoreceptor retinoid binding protein</topic><topic>Laboratory Science</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Ophthalmology</topic><topic>Proteins</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Retina - chemistry</topic><topic>retinal autoantigens</topic><topic>Retinol-Binding Proteins - administration & dosage</topic><topic>Retinol-Binding Proteins - immunology</topic><topic>S-antingen</topic><topic>Skin Tests</topic><topic>tolerance</topic><topic>Uvea diseases</topic><topic>Uveitis, Posterior - drug therapy</topic><topic>Uveitis, Posterior - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laliotou, Barbara</creatorcontrib><creatorcontrib>Liversidge, Janet</creatorcontrib><creatorcontrib>Forrester, John V</creatorcontrib><creatorcontrib>Dick, Andrew D</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laliotou, Barbara</au><au>Liversidge, Janet</au><au>Forrester, John V</au><au>Dick, Andrew D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>1997-01</date><risdate>1997</risdate><volume>81</volume><issue>1</issue><spage>61</spage><epage>67</epage><pages>61-67</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>AIMS Administration of unfractionated retinal antigen(s) (retinal extract, RE) suppresses RE induced experimental autoimmune uveoretinitis (EAU) and offers a potential therapeutic alternative to non-specific immunosuppressive therapies for posterior uveitis and autoimmune diseases. S-Ag and interphotoreceptor retinoid binding protein (IRBP) are two major autoantigens within soluble RE. It was aimed to assess, firstly, as has previously been shown with S-Ag, if IRBP can induce intranasal tolerance and, secondly, the contribution of both these major autoantigens to tolerance induction by whole RE. METHODS Animals were tolerised by intranasal administration with S-Ag or IRBP, either alone or in combination, or RE before immunisation with either IRBP or RE. Control animals were administered nasally either PBS or MBP. Daily clinical responses were recorded biomicroscopically and histological grades were obtained using a semiquantitative scoring system. Weekly serum antibody levels to retinal antigens were measured by ELISA and delayed hypersensitivity responses (DTH) were assessed by skin reactivity to intradermal inoculation with retinal or non-specific antigens. RESULTS Microgram doses of IRBP successfully suppressed both clinically and histologically IRBP induced EAU. This suppression was accompanied by reduced antigen specific DTH reactivity but maintained T cell dependent (IgG2a) antibody responses. Furthermore, combined S-Ag and IRBP administration afforded equal suppression of RE induced EAU when compared with RE therapy alone. Suppression of RE induced EAU was not achieved with administration of a non-retinal specific autoantigen, MBP. Although individually, both S-Ag and IRBP suppressed RE induced EAU, whole RE was unable to protect against IRBP induced disease. CONCLUSIONS Intranasal administration of IRBP suppressed IRBP induced EAU in the Lewis rat. S-Ag and IRBP are the major contributors to the tolerogenicity within RE, despite the known uveogenicity of other retinal antigens within RE and induction of tolerance was retinal antigen specific. Furthermore, suppression induced by single antigen administration is antigen specific although concomitant bystander suppression may also play a role. RE was unable to protect against IRBP induced disease despite tolerogenic levels of antigen within RE. Although this may be due in part to a dose effect of either tolerising or immunising antigen, further investigation into the possible antigen dominance of IRBP or mucosal processing of combinations of antigens is necessary so that the full efficacy of mucosal tolerance therapy can be assessed.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>9135411</pmid><doi>10.1136/bjo.81.1.61</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1161 |
ispartof | British journal of ophthalmology, 1997-01, Vol.81 (1), p.61-67 |
issn | 0007-1161 1468-2079 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1722010 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Administration, Intranasal Animals Antigens Arrestin - administration & dosage Arrestin - immunology Autoantigens - administration & dosage Autoantigens - immunology Autoimmune diseases Autoimmune Diseases - drug therapy Autoimmune Diseases - immunology Biological and medical sciences Disease Drug dosages Enzyme-Linked Immunosorbent Assay experimental autoimmune uveoretinitis Female Immune Tolerance - drug effects interphotoreceptor retinoid binding protein Laboratory Science Lymphocytes Medical sciences Ophthalmology Proteins Rats Rats, Inbred Lew Retina - chemistry retinal autoantigens Retinol-Binding Proteins - administration & dosage Retinol-Binding Proteins - immunology S-antingen Skin Tests tolerance Uvea diseases Uveitis, Posterior - drug therapy Uveitis, Posterior - immunology |
title | Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T23%3A43%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interphotoreceptor%20retinoid%20binding%20protein%20is%20a%20potent%20tolerogen%20in%20Lewis%20rat:%20suppression%20of%20experimental%20autoimmune%20uveoretinitis%20is%20retinal%20antigen%20specific&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Laliotou,%20Barbara&rft.date=1997-01&rft.volume=81&rft.issue=1&rft.spage=61&rft.epage=67&rft.pages=61-67&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjo.81.1.61&rft_dat=%3Cproquest_pubme%3E4012596501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778962471&rft_id=info:pmid/9135411&rfr_iscdi=true |